Question · asked by 1 review
Omega‐3 vs placebo: Pulmonary exacerbations
- Population
- adults and children with cystic fibrosis
- Intervention
- Omega‐3
- Comparison
- placebo
- Outcome
- Pulmonary exacerbations
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: omega‐3 fatty acid supplementation vs placebo Number of pulmonary exacerbations (median number of exacerbations during the study) · children and adults with cystic fibrosis Omega‐3 fatty acid supplementation for cystic fibrosis (2020) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 13 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.